Willemien J. van Driel

Dutch Cancer Society

Papers

1

Total Citations

26

H-Index

1

About

Willemien J. van Driel is a leading gynecologic oncologist whose research has fundamentally reshaped the surgical management of cervical cancer. Her primary focus lies in optimizing treatment for early-stage disease, specifically through de-escalation of radical surgery to reduce patient morbidity without compromising oncologic outcomes. Dr. van Driel’s most impactful contribution is her leadership in the landmark SHAPE trial (CCTG CX.5), a phase III randomized study comparing radical hysterectomy with simple hysterectomy for low-risk early-stage cervical cancer. This practice-changing work, published in 2023 and already cited 26 times, demonstrated that less radical surgery is non-inferior for recurrence while significantly lowering treatment-related side effects. Her findings have directly influenced international clinical guidelines, offering thousands of women a safer, less invasive surgical option. Dr. van Driel’s research exemplifies the power of high-quality, collaborative trials—conducted through the Gynecologic Cancer Intergroup—to challenge long-standing surgical dogma. For students and researchers, her work is a masterclass in evidence-based surgical de-escalation, proving that “less can be more” in oncology.

Research Focus

Key Achievements

1
H-Index
1
Papers
26
Total Citations
26
Avg Citations/Paper
🏆 Most Cited Paper
An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC): A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE).
26 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 19
🏛 Institutions: Dutch Cancer Society

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago